- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02648516
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution Failure in Chronic HIV-1 Infected Patients
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
There is not a consensus definition of immunologic nonresponder individuals. In this study, we described patients whose cluster of differentiation 4(CD4)+ T-cell count remained below 200 cells/ul after 2 years of effective antiviral as immunologic nonresponders, in which viroimmunological dissociation implies a greater risk of AIDS related and non-AIDS-related illnesses. Immune-based therapy such as interleukin (IL)-2 and IL-7 have been shown to increase CD4 T-cell counts but yielded no clinical benefit in a large randomized study. We have reported that umbilical cord Tissue Mesenchymal Stem Cells (UC-MSC) treatment is safe and can significantly decrease systemic immune overactivation and improve immune reconstitution in INR patients. Meanwhile, we did not find that there was a significantly transitory increase in peripheral CD4 T-cell counts within 1-2 weeks since the onset of each MSC infusion. More important, umbilical cord-MSCs were found to be with a potential to produce IL-7 and T-cell growth factor transforming growth factor (TGF)-β in vitro and in vivo and preferentially expand CD4 T-cell response in the recipients. Therefore, development of novel interventions to reduce immune overactivation/inflammation and enhance immune reconstitution in INRs is a high priority.
Granulocyte colony-stimulating factor (G-CSF)-mobilized donor peripheral blood mononuclear cells (MNCs) are a heterogeneous population of immune cells that have a potential role in immunomodulation and hemopoiesis. Here, we hypothesized that human leukocyte antigen (HLA)-mismatched MNCs transfusion can be used to comprehensively restore or boost the host holistic immune system for INR patients, to the degree similar as immune responders.
The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy (AAIT) for INR patients. 20 INR patients received i.v. transfusion one round (3 times) of 2.0-3.0*10E8 cells/kg of MNCs as the treated group. All of them received the conventional treatment for AIDS. The CD4 T cell numbers, HIV reservoir, side effects, symptom improvement, control of opportunistic infections and will be evaluated during the 96-week follow up.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Fu-Sheng Wang
- E-post: fswang302@163.com
Studera Kontakt Backup
- Namn: Yan-Mei Jiao
- E-post: jiaoyanmei@sina.com
Studieorter
-
-
Beijing
-
Beijing, Beijing, Kina, 100069
- Rekrytering
- Beijing 302 Hospital
-
Kontakt:
- Ji-yuan Zhang, PhD
-
Kontakt:
- Yan-mei Jiao, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Immune non-responders with chronic HIV-1 infection
- Antiretroviral therapy (ART) for at least 24 months prior to study entry and continue within the 24 months after study entry
- CD4 count less than or equal to 200 cells/mm3 continuously and more than 50 cells/mm3 before entry and at screening, obtained within 30 days prior to study entry
- Viral load less than or equal to 50 copies/mL obtained within 12 months prior to study entry
- Certain specified laboratory values obtained within 30 days prior to study entry. More information on this criterion can be found in the study protocol
- Documentation that pre-entry specimen for the primary immune activation endpoint responses has been obtained
- No history of Centers for Disease Control and Prevention (CDC) category C AIDS-related opportunistic infections
- Karnofsky performance score greater than or equal to 70 within 30 days prior to study entry
- Ability and willingness to provide informed consent
Exclusion Criteria:
- Coinfection with other virus, including serum hepatitis C virus RNA positive, or one of followings are positive in anti-hepatitis A virus/anti-HDV/anti-hepatitis delta virus plus alanine aminotransferase (ALT) more than 80 IU/L
- History of combination with other severe diseases including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors
- White blood cell (WBC) <2.5*10E9/L, platlet counts <50*10E9/L, Hb <80g/L, lactate >2 mmol/L
- Allergic constitution
- Pregnancy or lactation
- Accepting other immunomodulatory drugs within 6 months prior screening
- Drug addiction
- Other conditions possibly influencing the trial
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Conventional plus AAIT
Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
|
Participants will receive ART and taken i.v., at a dose of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The changes of CD4 T cell counts
Tidsram: At Baseline and week 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
|
marker for host immunity
|
At Baseline and week 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The changes of HIV-1 DNA
Tidsram: At Baseline and up to week 96
|
marker for HIV-1 reservoir
|
At Baseline and up to week 96
|
The ratio of CD4 and CD8 T cells
Tidsram: At Baseline and week 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
|
marker for host immunity
|
At Baseline and week 1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Tidsram: At Baseline and up to week 96
|
marker for safety
|
At Baseline and up to week 96
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Wang Fu-Sheng, Beijing 302 Hospital
Publikationer och användbara länkar
Allmänna publikationer
- Hutter G. Stem cell transplantation in strategies for curing HIV/AIDS. AIDS Res Ther. 2016 Sep 13;13(1):31. doi: 10.1186/s12981-016-0114-y. eCollection 2016.
- Zhang Z, Fu J, Xu X, Wang S, Xu R, Zhao M, Nie W, Wang X, Zhang J, Li T, Su L, Wang FS. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS. 2013 May 15;27(8):1283-93. doi: 10.1097/QAD.0b013e32835fab77.
- Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood. 2011 May 26;117(21):5582-90. doi: 10.1182/blood-2010-12-322453. Epub 2011 Mar 14.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- Långsamma virussjukdomar
- HIV-infektioner
- Förvärvat immunbristsyndrom
Andra studie-ID-nummer
- Beijing302-010
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Humant immunbristvirus
-
University Hospital, LimogesRekrytering
-
Centre Hospitalier Universitaire, AmiensAvslutad
-
Bristol-Myers SquibbAvslutad
-
ANRS, Emerging Infectious DiseasesHar inte rekryterat ännuHepatit B-virus - kroniskt aktivt
-
Janssen-Cilag International NVAvslutadInfektioner av humant immunbristvirus (HIV). | Aids-virus (Acquired Immunodeficiency Syndrome).Frankrike, Storbritannien, Belgien, Tyskland, Spanien, Schweiz, Danmark, Israel, Österrike, Polen, Ungern, Sverige, Irland
-
Corporacion Parc TauliAvslutadKronisk leversjukdom | Hepatit B-virusSpanien
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health...AvslutadInfektion med hepatit C-virus (HCV).Förenta staterna
-
AbbVieAvslutadKronisk hepatit C | Hepatit C-virus | Genotyp 3 Hepatit C-virus
-
AbbVieAvslutadHepatit C-virus | Kroniskt hepatit C-virus
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrytering
Kliniska prövningar på Conventional plus AAIT
-
Beijing 302 HospitalAvslutadHumant immunbristvirus | Immunbrist
-
Inonu UniversityHar inte rekryterat ännuStroke | Motoriska bilder | Action Observation Training | Graderade motorbilderKalkon
-
The University of Tennessee, KnoxvilleNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) och andra samarbetspartnersAvslutadFetma | BarnfetmaFörenta staterna
-
ResMedAvslutad
-
Ethicon, Inc.Avslutad
-
Alma Lasers Inc.Okänd
-
University of TrierGerman Research FoundationAvslutadFeedback, PsykologiskTyskland
-
Farmaceutici Damor SpaRekryteringSår och skador | Sårinfektion | SårläkningItalien
-
Johns Hopkins UniversityNational Institute on Aging (NIA); University of MinnesotaRekrytering
-
National Institute of Diabetes and Digestive and...Avslutad